|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Rationale of Checklist** | | | |  |
| This checklist will be completed by the CPHIOW sub-committee for every new or recommissioned service specification sent to CPHIOW for comment/consultation. The response summary is completed after consultation and agreement by the sub-committee.  The Checklist contains the CPHIOW sub-committee’s comments/recommendations for any requested changes to the proposed/draft service specification in order to achieve / improve further the green rating. It will be sent to the service commissioner for consideration of amendments ideally prior to go-live of the service.  CPHIOW’s purpose is to work positively with commissioners to ensure high quality outcomes from the service, which are both professionally and commercially viable for contractor participation. | | | |  |
| **Service and Commissioner** | | | |  |
| Supply of Oral Antiviral Medication for Treatment of COVID-19 and Influenza  Hampshire & Isle of Wight ICB | | | |  |
| **Response summary feedback from CPHIOW** | | | |  |
|  | | | |  |
| CPHIOW has rated this service specification as Green based on the comments made below. Our recommended actions to further improve the service are:   1. Electronic claiming rather than paper. | | | |  |
| **Time-line & Next Steps for CPHIOW** | | | |  |
| CPHIOW will publish this service participation rating to contractors in **10 days’ time.**  Publication of this recommendation will be via individual email and posting on our website.  Commissioners are asked to please respond promptly with feedback / proposed changes so that they can be included within CPHIOW’s recommendation to its contractors. | | | |  |
| **Commissioners response to CPHIOW feedback** | | | |  |
| Please enter response here, returning promptly to [alison.freemantle@CPSC.org.uk](mailto:alison.freemantle@CPSC.org.uk) | | | |  |
| **Point Covered** | | | **Action or Notes** |  |
|  | | **CPHIOW Consultation** | |  |
| CPHIOW Consulted? | | | Yes |  |
| CPHIOW Consulted with sufficient time to comment? | | | Yes |  |
|  | | **Remuneration** | |  |
| Does remuneration include/cover set up costs, backfill, consumables etc..? | | | Some.  Initial cost of covid antivirals can be immediately claimed for. Flu antivirals can be claimed if go out of date. |  |
| Does the payment structure use a system that is suitable for all contractors and are the payment terms acceptable? | | | Annual retainer with be automatically invoice every 6 months via PharmOutcomes.  Claiming for out of date stock or deliveries is a paper based form. |  |
| Where equipment is required who provides/calibrates/services this? If contractor, does remuneration sufficiently cover the cost of this? | | | No equipment needed. |  |
| Is remuneration fair? | | | Yes |  |
|  | **Is/does the Service.....** | | |  |
| Sustainable? | | | Yes |  |
| Start/ end date | | | 25th September 2025 – 31st July 2027 |  |
| Clinically sound and in line with appropriate National or local guidance? | | | Yes  NHS England has set out requirements that local systems work with system partners to transition to routine access to COVID-19 treatments, in line with NICE recommendations. NICE TA878 and NICE TA1056, |  |
| Enhance patient care? | | | Yes  Provides patients with ease of access to anti virals when treatment is time sensitive. |  |
| Have suitable monitoring arrangements and termination clauses? | | | Termination 3 months written notice during the life of the LCS.  Adequate records must be maintained for pre and post payment verification, should this be required. |  |
| Enhance relationships with other HCPs? | | | Yes  Especially staff at the CMDU/ PHL out of hours service who will be writing the prescriptions. |  |
| Equality, diversity, and inclusion considered? | | | Yes, service is accessible to all patients needing an antiviral prescription dispensed. |  |
| Deliverable? | | | Yes |  |
| Delivery impact on staff (High/ Medium/Low) | | | Low |  |
| Attractive enough for contractors to consider it worthwhile? | | | Yes |  |
| Have performance criteria that supports a quality service? | | | Only performance criteria will be to ensure have correct stock levels in place. |  |
|  | **Service Delivery** | | |  |
| Are the performance measures reasonable and achievable? | | | Yes |  |
| Is the administration proportional to size or service and remuneration? | | | Yes |  |
| Are any reporting systems suitable to all contractors? | | | Use of PharmOutcomes for automatic payment of retainer.  Paperbased for all other activity. |  |
| Is the training required for the service reasonable? Consider accessibility to CPPE for non-pharmacist/technician staff. | | | Yes, no mandatory training.  There is a suggestion of self directed learning for pharmacy staff. |  |
| Does record keeping or sharing of information requirements meet current IG regulations. | | | No patient identifiable records need to be kept or shared. |  |
|  | **Miscellaneous Information** | | |  |
| Any other information specific to this service. | | | Better funding than the current Frimley spec. |  |
| Suggested RAG Rating | | |  |  |